Quick Answer
Allarity Therapeutics, Inc. reported Net Income of -$11.23 million for fiscal year 2025.
Allarity Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$11.23M +54.2% |
-$24.52M -106.0% |
-$11.90M +25.9% |
-$16.06M +39.7% |
-$26.65M -302.7% |
-$6.62M |
| Diluted EPS | — | — | -$10.26 +99.7% |
-$3093.42 -73728.6% |
-$4.19 | — |
| Total Assets | $18.26M -19.4% |
$22.65M +90.9% |
$11.86M -18.4% |
$14.54M -70.7% |
$49.63M +48.6% |
$33.40M |
| Cash and Equivalents | $14.69M -24.8% |
$19.53M +11666.9% |
$166.0K -91.8% |
$2.03M | — | — |
| Stockholders Equity | $9.83M -16.8% |
$11.81M +529.3% |
-$2.75M -2334.5% |
-$113.0K -100.6% |
$18.15M -25.7% |
$24.44M +22.0% |
| R&D Expense | $6.60M +8.3% |
$6.10M -14.2% |
$7.10M +2.5% |
$6.93M -51.2% |
$14.20M +236.6% |
$4.22M |
| Operating Income | -$12.61M +53.7% |
-$27.24M -59.0% |
-$17.13M +50.3% |
-$34.46M -29.8% |
-$26.56M -219.2% |
-$8.32M |
| Shares Outstanding | 16.08M +120.2% |
7.30M +74327.2% |
9,812 -13.6% |
11,356 -99.9% |
8.10M +90.4% |
4.25M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$2.81M | +75.8% | -20.9% |
| Diluted EPS | June 30, 2024 | -$0.11 | +100.0% | +99.5% |
| Total Assets | September 30, 2025 | $20.80M | +2.1% | -1.9% |
| Cash and Equivalents | September 30, 2025 | $16.89M | — | -5.1% |
| Stockholders Equity | September 30, 2025 | $12.01M | -7.4% | -1.3% |
| R&D Expense | September 30, 2025 | $1.20M | +17.8% | -48.2% |
| Operating Income | September 30, 2025 | -$2.52M | +79.6% | +39.1% |
| Shares Outstanding | September 30, 2025 | 16.11M | +483.9% | +10.2% |
- Allarity Therapeutics, Inc. reported Net Income of -$11.23 million for fiscal year 2025.
- Allarity Therapeutics, Inc. showed an increase of +54.2% in Net Income compared to the prior fiscal year.
- Allarity Therapeutics, Inc. reported Diluted EPS of $10.26 per share (loss) for fiscal year 2023.
- Allarity Therapeutics, Inc. showed an increase of +99.7% in Diluted EPS compared to the prior fiscal year.
- Allarity Therapeutics, Inc. reported Total Assets of $18.26 million for fiscal year 2025.
- Allarity Therapeutics, Inc. showed a decrease of -19.4% in Total Assets compared to the prior fiscal year.
- Allarity Therapeutics, Inc. reported Cash and Equivalents of $14.69 million for fiscal year 2025.
- Allarity Therapeutics, Inc. showed a decrease of -24.8% in Cash and Equivalents compared to the prior fiscal year.
- Allarity Therapeutics, Inc. reported Stockholders Equity of $9.83 million for fiscal year 2025.
- Allarity Therapeutics, Inc. showed a decrease of -16.8% in Stockholders Equity compared to the prior fiscal year.
- Allarity Therapeutics, Inc. reported R&D Expense of $6.60 million for fiscal year 2025.
- Allarity Therapeutics, Inc. showed an increase of +8.3% in R&D Expense compared to the prior fiscal year.
- Allarity Therapeutics, Inc. reported Operating Income of -$12.61 million for fiscal year 2025.
- Allarity Therapeutics, Inc. showed an increase of +53.7% in Operating Income compared to the prior fiscal year.
- Allarity Therapeutics, Inc. reported Shares Outstanding of 16.08 million shares for fiscal year 2025.
- Allarity Therapeutics, Inc. showed an increase of +120.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: